NASDAQ$RNA

Atrium Therapeutics Inc · Q2 2025 earnings

Q2 2025 earnings ·

Briefing

RNA Q2 2025 — $3.8M revenue, 1.21 EPS

Any of these actions could materially harm the Company’s business, results of operations and future prospects. Atrium Therapeutics Inc reported Q2 2025 results. Diluted EPS came in at $1.21. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.

  • Revenue: $3.8M.
  • Diluted EPS: $1.21.
  • Filed on Form 10-Q (accession 0001599901-25-000148).

Headline financials

Total Revenue

$3.85M

Previous: $2.05M+88.1%
EPS (adj)

$1.21

Previous: -$0.65+286.2%
Capital Expenditures

-$7.1M

Previous: -$1.45M-390.7%
Free Cash Flow

-$164M

Previous: -$72.2M-127.6%
Net Income

-$157M

Previous: -$70.8M-122.2%
Operating Income

-$171M

Previous: -$82.6M-107.1%

Revenue & EPS history

Atrium Therapeutics Inc · Revenue · Quarterly

$3.85M

Q2 2025+88.1%vs Q2 2024
Beat estimate in 1 of 1 quarters(100%)
ActualEstimate

Revenue by segment

Atrium Therapeutics Inc · $19.6M total across 1 segment · Q1 2026

  • Reportable Segment
    $19.6M—

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro